Tibet Rhodiola Pharmaceutical Holding Co.

SHSE:600211 Stock Report

Market Cap: CN¥12.0b

Tibet Rhodiola Pharmaceutical Holding Past Earnings Performance

Past criteria checks 2/6

Tibet Rhodiola Pharmaceutical Holding has been growing earnings at an average annual rate of 21.2%, while the Healthcare industry saw earnings growing at 2% annually. Revenues have been growing at an average rate of 20.5% per year. Tibet Rhodiola Pharmaceutical Holding's return on equity is 20.2%, and it has net margins of 25.1%.

Key information

21.2%

Earnings growth rate

20.9%

EPS growth rate

Healthcare Industry Growth7.0%
Revenue growth rate20.5%
Return on equity20.2%
Net Margin25.1%
Last Earnings Update30 Sep 2024

Recent past performance updates

Shareholders Will Be Pleased With The Quality of Tibet Rhodiola Pharmaceutical Holding's (SHSE:600211) Earnings

May 03
Shareholders Will Be Pleased With The Quality of Tibet Rhodiola Pharmaceutical Holding's (SHSE:600211) Earnings

Recent updates

Investors Holding Back On Tibet Rhodiola Pharmaceutical Holding Co. (SHSE:600211)

Nov 27
Investors Holding Back On Tibet Rhodiola Pharmaceutical Holding Co. (SHSE:600211)

At CN¥33.30, Is Tibet Rhodiola Pharmaceutical Holding Co. (SHSE:600211) Worth Looking At Closely?

Sep 25
At CN¥33.30, Is Tibet Rhodiola Pharmaceutical Holding Co. (SHSE:600211) Worth Looking At Closely?

Tibet Rhodiola Pharmaceutical Holding (SHSE:600211) Could Easily Take On More Debt

Sep 02
Tibet Rhodiola Pharmaceutical Holding (SHSE:600211) Could Easily Take On More Debt

Insufficient Growth At Tibet Rhodiola Pharmaceutical Holding Co. (SHSE:600211) Hampers Share Price

Jul 29
Insufficient Growth At Tibet Rhodiola Pharmaceutical Holding Co. (SHSE:600211) Hampers Share Price

Investors Shouldn't Overlook Tibet Rhodiola Pharmaceutical Holding's (SHSE:600211) Impressive Returns On Capital

Jul 12
Investors Shouldn't Overlook Tibet Rhodiola Pharmaceutical Holding's (SHSE:600211) Impressive Returns On Capital

Tibet Rhodiola Pharmaceutical Holding (SHSE:600211) Seems To Use Debt Rather Sparingly

May 21
Tibet Rhodiola Pharmaceutical Holding (SHSE:600211) Seems To Use Debt Rather Sparingly

Shareholders Will Be Pleased With The Quality of Tibet Rhodiola Pharmaceutical Holding's (SHSE:600211) Earnings

May 03
Shareholders Will Be Pleased With The Quality of Tibet Rhodiola Pharmaceutical Holding's (SHSE:600211) Earnings

Under The Bonnet, Tibet Rhodiola Pharmaceutical Holding's (SHSE:600211) Returns Look Impressive

Mar 22
Under The Bonnet, Tibet Rhodiola Pharmaceutical Holding's (SHSE:600211) Returns Look Impressive

Revenue & Expenses Breakdown

How Tibet Rhodiola Pharmaceutical Holding makes and spends money. Based on latest reported earnings, on an LTM basis.

Earnings and Revenue History

SHSE:600211 Revenue, expenses and earnings (CNY Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Sep 242,9427371,75726
30 Jun 242,9298281,76720
31 Mar 242,9328111,77116
31 Dec 233,1348011,88117
30 Sep 232,9647821,79317
30 Jun 233,0327031,81819
31 Mar 232,8054981,68583
31 Dec 222,5553701,54188
30 Sep 222,5352331,533122
30 Jun 222,4441731,466133
31 Mar 222,3002261,36669
31 Dec 212,1392091,25361
30 Sep 211,9455121,11323
30 Jun 211,7824961,01410
31 Mar 211,5714478848
31 Dec 201,3734187487
30 Sep 201,3143987047
30 Jun 201,26637567010
31 Mar 201,2563706589
31 Dec 191,25631268211
30 Sep 191,21822467011
30 Jun 191,1942436419
31 Mar 191,11221859411
31 Dec 181,0282165488
30 Sep 181,0143264929
30 Jun 189333014558
31 Mar 188832444275
31 Dec 179162304284
30 Sep 179472154530
30 Jun 179801954520
31 Mar 179462324540
31 Dec 167971984010
30 Sep 166651453820
30 Jun 167201293590
31 Mar 161,0131033570
31 Dec 151,383923610
30 Sep 151,678543450
30 Jun 151,820253370
31 Mar 151,762213100
31 Dec 141,668212970
30 Sep 141,647442830
30 Jun 141,547382700
31 Mar 141,465322640
31 Dec 131,402272470

Quality Earnings: 600211 has a large one-off loss of CN¥210.6M impacting its last 12 months of financial results to 30th September, 2024.

Growing Profit Margin: 600211's current net profit margins (25.1%) are lower than last year (26.4%).

Free Cash Flow vs Earnings Analysis

Past Earnings Growth Analysis

Earnings Trend: 600211's earnings have grown significantly by 21.2% per year over the past 5 years.

Accelerating Growth: 600211's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.

Earnings vs Industry: 600211 had negative earnings growth (-5.7%) over the past year, making it difficult to compare to the Healthcare industry average (-5.7%).

Return on Equity

High ROE: 600211's Return on Equity (20.2%) is considered high.

Return on Assets

Return on Capital Employed

Discover strong past performing companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/22 02:15
End of Day Share Price 2024/12/20 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Tibet Rhodiola Pharmaceutical Holding Co. is covered by 6 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Weina JiangEverbright Securities Co. Ltd.
Wen Liang CuiFounder Securities Co., Ltd.
Zhouyu DengGuosen Securities Co., Ltd.